Richard Jirovec
Family Medicine · Lincoln, NENPI 1033168174
Payments from drug & device makers
Across 100 payments — averaging $38.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sekisui Diagnostics LLC$1K
- Novo Nordisk$489
- Sanofi US Services Inc.$350
- AstraZeneca$339
- AbbVie$272
- BD$183
- plus $1K from 20 others
What the payments were for
- Consulting fees$3138%
- Speaking & faculty fees$49013%
- Food & beverage$1,86148%
- Education$60%
- Gifts$1,19031%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sekisui Diagnostics LLC | 3 | $1,190 |
| Novo Nordisk | 34 | $489 |
| Sanofi US Services Inc. | 1 | $350 |
| AstraZeneca | 10 | $339 |
| AbbVie(2 entities) | 11 | $272 |
| BD | 1 | $183 |
| Bayer | 4 | $177 |
| Lilly USA, LLC | 7 | $157 |
| GSK | 6 | $103 |
| Comsort, Inc | 1 | $100 |
| Sanofi-aventis U.S. LLC | 2 | $80 |
| Sanofi | 1 | $60 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Antares Pharma, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Amgen | 2 | $39 |
| Pfizer | 2 | $29 |
| Abbott | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$350
- FARXIGA$125
- Kerendia$125
- SIVEXTRO$100
How this compares
$3,861 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 23 | $26,273 |
| JardianceEmpagliflozin | 21 | $18,499 |
| FarxigaDapagliflozin Propanediol | 16 | $17,910 |
| Metoprolol Succinate | 43 | $715 |
| Simvastatin | 40 | $550 |
| Losartan Potassium | 56 | $545 |
| Rosuvastatin Calcium | 38 | $476 |
| Amlodipine Besylate | 60 | $442 |
| Atorvastatin Calcium | 62 | $432 |
| Pantoprazole Sodium | 40 | $370 |
| Gabapentin | 18 | $307 |
| Levothyroxine Sodium | 53 | $301 |
| Metformin Hcl ErMetformin Hcl | 27 | $238 |
| Duloxetine Hcl | 12 | $232 |
| Omeprazole | 18 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $157 | $26,27323 claims |
| Boehringer IngelheimJardiance | $17 | $18,49921 claims |
| AstraZenecaFarxiga | $339 | $17,91016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lincoln
- Allen HuntLincoln$17.2M
- Michael IsraelLincoln$375K
- Randy KohlLincoln$67K
- Matthew GlennLincoln$17K
- Uma NookaLincoln$12K
- Kylie ParshallLincoln$12K
- Michael HuffmanLincoln$11K
- Svjetlana DzikoLincoln$11K
- Eric JohnsonLincoln$10K
- Gary van ErtLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.